News Releases

Date Title and Summary
Toggle Summary electroCore Announces Second Quarter 2021 Financial Results
Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET ROCKAWAY, NJ , Aug. 05, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc.
Toggle Summary Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress
ROCKAWAY, NJ , Aug. 10, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, “Transcutaneous Cervical Vagal Nerve Stimulation (tcVNS/nVNS) in Patients with Posttraumatic Stress
Toggle Summary electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.
ROCKAWAY, NJ , Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC . (Red One). The partnership will further expand availability of electroCore’s gammaCore
Toggle Summary electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference
ROCKAWAY, NJ , Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference .
Toggle Summary electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua
ROCKAWAY, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the
Toggle Summary electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices
ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods
Toggle Summary electroCore Announces Peter Cuneo as Board Chairman
ROCKAWAY, NJ , Sept. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter Cuneo as Chairman of the Board of Directors effective October 1, 2021 . Mr.
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, NJ , Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference .  The
Toggle Summary electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
ROCKAWAY, NJ , Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve
Toggle Summary electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
ROCKAWAY, NJ , Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30,